INTRODUCTION
Bovine spongiform encephalopathy (BSE) is a fatal neurodegenerative disorder of cattle, and belongs to a group of diseases known as transmissible spongiform encephalopathies (TSEs) or prion diseases. The main characteristic of BSE is the accumulation in the brain of PrP TSE , which is a protease-resistant conformational variant of the normal host-encoded cellular prion protein (PrP C ). BSE was first reported in the UK in 1987 (Bruce et al., 1997; Wells et al., 1987) , and its transmission to humans through the consumption of contaminated food is thought to be the cause of the variant form of CreutzfeldtJakob disease (vCJD) (Bruce et al., 1997; Hill et al., 1997) . Whilst a number of other animal TSEs exist, including scrapie in sheep and goats and chronic wasting disease in cervids, BSE is the only TSE known to be naturally transmissible from animals to humans. Previously, TSE disease in cattle was believed to be caused by a single prion strain, known as classical BSE (BSE-C). However, due to the initiation of a large-scale surveillance programme throughout Europe, two atypical BSE agents were reported (Biacabe et al., 2004; Casalone et al., 2004; Jacobs et al., 2007; Stack et al., 2009 ) and identified as BSE-H and bovine amyloidotic spongiform encephalopathy (BASE, also named BSE-L). BSE-H and BASE were originally described in 2004 in France (Biacabe et al., 2004) and Italy (Casalone et al., 2004) , respectively. However, these atypical BSE strains have since been identified in other European countries (Jacobs et al., 2007) , Japan (Hagiwara et al., 2007) and North America (Dudas et al., 2010; Richt et al., 2007) . Several studies have shown that, following transmission into transgenic mice that overexpress the bovine prion protein, these atypical BSE agents show neuropathological and molecular phenotypes that are distinct from BSE-C, indicating that they are different BSE strains (Béringue et al., 2006 (Béringue et al., , 2007 Buschmann et al., 2006; Capobianco et al., 2007; Okada et al., 2010) . Indeed, BASE and BSE-H can be distinguished by the electrophoretic migration of their protease-resistant PrP TSE isoforms
and their different patterns of glycosylation (Biacabe et al., 2004; Buschmann et al., 2006; Casalone et al., 2004; Jacobs et al., 2007) . Interestingly, however, studies have shown the conversion of both BASE and BSE-H to BSE-C when passaged through WT mice (Baron et al., 2011; Capobianco et al., 2007) .
Previously, we modelled the possible susceptibility of humans to BASE and BSE-H using gene-targeted human PrP transgenic (HuTg) mice (Wilson et al., 2012b) . In humans, susceptibility to TSE infection is linked to a polymorphism in the human PrP gene at codon 129 (Zeidler et al., 1997) . (Bishop et al., 2006) . By crossing the homozygous 129MM and 129VV lines, we can also produce a true 129MV heterozygote (HuMV). Following inoculation of these atypical BSE agents in HuTg mice, we did not detect any signs of TSE disease pathology (Wilson et al., 2012b) , suggesting that the transmission barrier was significant in the presence of human PrP, and that the risk of disease transmission from atypical BSE was low. However, we could not rule out the possibility that disease transmission in the presence of human PrP may be inefficient, and that the HuTg mice that survive for their lifespan may be able to maintain low-level agent replication in the central nervous system. Indeed, primary transmission of prion diseases between different species is often challenging, and although this subclinical infection does not result in TSE disease during the lifespan of the animal, the replication of low levels of infectivity in an animal may pose a risk of accidental transmission through routes such as surgery and blood transfusion. Therefore, the presence of subclinical forms of TSE infection resulting from atypical BSE could present a major public health risk, and warrants further investigation.
To address the potential for subclinical infection in animals expressing human PrP following exposure to atypical BSE, we performed subpassage experiments from several HuTg brains challenged with BASE or BSE-H into HuTg mice and Bov6 Tg mice (expressing bovine PrP). In the present study, we found evidence of subclinical infection in one HuMM and one HuVV Tg mouse challenged with BASE. These findings suggest that low-level replication of BASE can occur in hosts expressing human PrP; however, the efficiency of any potential mouse-to-mouse transmission in hosts expressing human PrP appears to be low.
RESULTS

Subpassage of brain tissue from BASEchallenged HuTg mice into Bov6 Tg mice
Brain tissues harvested from previous transmission studies of BASE and BSE-H into HuTg mice (Wilson et al., 2012b) was examined for evidence of TSE agent replication by bioassay in HuTg or Bov6 mice. Several different tissues were analysed (see Table 1 The lesion profiles, which define areas of vacuolation and their degree of severity in the brain, were determined for Bov6 mice inoculated with controls C18275-Bov6 and C19414-Bov6 (Fig. 1) . Although the production of lesion profiles in pre-clinical mice is not standard practice, all mice challenged with C18275-Bov6 and C19414-Bov6 that scored positively for vacuolation pathology were included to give an indication of vacuolation profile. Lesion profile patterns of primary and secondary passages of BASE or BSE-H in Bov6 mice were similar between the same BSE agent (Fig. 1) , although higher levels of vacuolation were observed in areas 8 and 9 of the grey matter and in the white matter in BASE subpassage mice. This difference may be due to these mice being non-clinical and culled at different stages of pre-clinical disease, or adaptation of the agent to the murine host on subpassage. Due to the low number of animals that scored positively for vacuolation pathology and lack of statistical significance, lesion profiles from Bov6 mice challenged with C18985-HuMM or C19409-HuVV were not included.
Neuropathology
PrP deposition in the thalamus, medulla (Fig. 2a, b and Fig.  S1 , available in JGV Online), midbrain and caudate was detected using immunohistochemistry in Bov6 mice challenged with C18985-HuMM. Similarly, one Bov6 mouse challenged with C19409-HuVV showed PrP deposition in the same brain regions, although the staining was not as heavy ( Fig. 2c, d ). Control Bov6 mice challenged with C18275-Bov6 showed widespread heavy PrP deposition (Fig. 2e , f and Fig. S1 ), unlike control Bov6 mice challenged with C19414-Bov6, which only showed sparse PrP deposition (Fig. 2g, h ). Bov6 mice challenged with C18985-HuMM, C19409-HuVV and C18275-Bov6 showed Table 1 . Tissues used for subpassage into HuTg and Bov6 Tg mice Reference numbers in bold represent the tissue from which disease transmission was observed (see Table 2 ). Subclinical infection in HuTg mice exposed to BASE plaque-like PrP deposits which stained dark brown. Whilst Bov6 mice challenged with C19414-Bov6 also showed plaque-like PrP deposition, these deposits were not as heavily stained. To control for age-related effects, gliosis was first assessed in brain tissue obtained from a previous ageing study of Bov6 mice (Wilson et al., 2012a) . Mild gliosis was present throughout the brains of these mice (Fig. 3a, b) . In contrast to gliosis due to ageing, an obvious increase in the appearance of astrogliosis was clearly evident throughout the brains of Bov6 mice inoculated with C18985-HuMM, C18275-Bov6 and C19414-Bov6 (Fig. 3d, g, j) . Whilst Bov6 mice challenged with C18275-Bov6 showed a marked increase in microgliosis (Fig. 3h ) compared with the uninfected aged Bov6 control, the increase in microgliosis in Bov6 challenged with C18985-HuMM was not as pronounced ( Fig. 3e ) and, interestingly, the microgliosis observed in Bov6 mice challenged with C19414-Bov6 (Fig. 3k) was not dissimilar to that seen in the uninfected aged Bov6 control mice. Interestingly, the presence of PrP deposition correlated with astrogliosis and microgliosis (Fig. 3i ) in Bov6 mice challenged with C18275-Bov6. However, despite obvious astrogliosis, no or very little PrP deposition was observed in the hippocampus of Bov6 mice challenged with C18985-HuMM (Fig. 3f ) or C19414-Bov6 (Fig. 3l ).
Molecular profile of PrP TSE in Bov6 mice inoculated with C18985, C18275 and C19414
Brains from Bov6 mice challenged with C18985-HuMM, C18275-Bov6 and C19414-Bov6 (two brains per isolate) were examined for the presence of PrP TSE by Western blotting. Brains from primary transmission of Bov6 mice challenged with BASE, BSE-H or BSE-C were also included for comparison. All brains selected for analysis were from mice that survived challenge to ¢418 days post-inoculation, and immunohistochemical analysis showed PrP deposition in all selected animals. Following Western blot analysis, proteinase K-resistant PrP TSE was present in the brains of Bov6 mice challenged with C18275-Bov6, C19414-Bov6 (Fig. 4a, b ) and C18985-HuMM (Fig. 4b) . Furthermore, these agents produced distinct PrP TSE profiles. Similar to primary transmissions of BASE into Bov6 mice, we found that the C18275-Bov6 PrP TSE unglycosylated isoform had a lower molecular mass than BSE-C and a distinct PrP TSE glycoform pattern (Fig. 4a) . Likewise, we found that the C19414-Bov6 PrP TSE unglycosylated isoform had a higher molecular mass than BSE-C or BASE and was similar to the PrP TSE molecular profile from primary transmissions of BSE-H into Bov6 mice (Fig. 4a) . These results are consistent with studies using transgenic overexpressing bovine PrP mice (Béringue et al. Fig. 1 . Pattern of vacuolation observed in brains of Bov6 mice derived from the first and second passage of BASE or BSE-H. A profile was produced from nine grey-matter areas (1, medulla; 2, cerebellum; 3, superior colliculus; 4, hypothalamus; 5, thalamus; 6, hippocampus; 7, septum; 8, retrospinal cortex; 9, cingulate and motor cortex) and three white-matter areas (11, cerebellar white matter; 12, midbrain white matter; 13, cerebral peduncle). Mean scores were taken from a minimum of seven mice per group and plotted against brain area. 2007; Okada et al., 2010) . Due to low levels of C18985-HuMM PrP TSE , it was difficult to fully resolve the glycoform pattern, although we did observe a heavier diglycosylated band, which may be suggestive of a BSE-like PrP TSE profile (Fig. 4b) . However, further subpassage experiments in Bov6 mice would be required to establish the presence of BSE-C or BASE.
Investigating the presence of PrP TSE in the brains of BASE-challenged HuMM mice Previously, we performed primary inoculations of BASE into HuMM mice but did not detect any signs of TSE neuropathology (Wilson et al., 2012b) . Due to the observed transmission of TSE from one of the HuMM mice selected for subpassage, and the possibility of subclinical infection, brain tissue from the 15 remaining HuMM mice that received the primary BASE inoculum were assayed for accumulation of PrP using a rapid TSE diagnostic assay. The IDEXX HerdChek* Bovine BSE Antigen Test kit, which is an antigen-capture enzyme immunoassay, utilizes a unique Seprion ligand capture technology (Microsens Biotechnologies) to identify the presence of aggregated PrP in the brain and has been used successfully on HuTg tissue in previous experiments (Plinston et al., 2011) . All assay readouts for the 15 brain tissues examined were negative, indicating the lack of PrP TSE within these brains.
DISCUSSION
In this study, knock-in transgenic mice expressing human PrP were utilized to model the potential risks posed to humans from exposure to atypical BSE agents. Whilst the use of transgenic mice does not accurately mimic infection of humans, they provide a model system in which TSE infection in the presence of human PrP can be examined in comparison with genetically identical control lines expressing either bovine PrP or WT murine PrP. Data cannot be fully extrapolated to humans but can provide some indication of potential risk. Three gene-targeted HuTg mouse lines were utilized, representing the genetic diversity in the human population due to the PrP codon 129 methionine/valine polymorphism (HuMM, HuMV and HuVV). As these mice are produced by gene replacement, they do not suffer from any adverse phenotypes observed in standard transgenic lines and may more accurately model what happens in nature. Our previous studies showed that, following primary transmissions of BASE and BSE-H into HuTg mice, we could not detect any pathological signs of TSE disease (PrP deposition and vacuolar pathology) in any of the mice (Wilson et al., 2012b ). In the current study, we re-examined all remaining tissues from the BASE-inoculated HuMM Tg mice using a C18275-Bov6 rapid TSE diagnostic assay (IDEXX) to investigate the presence of PrP TSE in the brains of HuTg mice challenged with BASE. This assay was employed to ensure that no PrP deposition was missed due to the level of sectioning of the tissue block and to assay for any forms of abnormal PrP that may not have been identified by immunohistochemistry. However, all IDEXX results on the 15 HuMM tissues examined were negative. Although the identification of PrP TSE by immunohistochemistry or IDEXX assay is an indication of TSE disease, the only method by which TSE infectivity can be identified is bioassay. To address the potential for subclinical infection and low-level agent replication in animals expressing human PrP, we performed subpassage experiments from HuTg brains following primary challenge with BASE or BSE-H into HuTg and Bov6 Tg mice. Upon subpassage, we found evidence of subclinical infection in both a HuMM and a HuVV Tg mouse challenged with BASE, demonstrated by the pathological signs of TSE disease (PrP deposition and/or vacuolar pathology) observed in five Bov6 Tg mice (four in the HuMM challenge and one in the HuVV challenge). However, no TSE disease transmission was observed in the HuTg mice following subpassage.
The existence of subclinical TSE infection in humans and animals has been documented previously (Hill & Collinge, 2003a, b; Race et al., 2001 Race et al., , 2002 . One such study showed that the cross-species passage of hamster 263K scrapie into WT mice appeared not to transmit, with the mice appearing clinically normal with no PrP TSE detectable. However, upon subpassage of brain tissue from a PrP TSEnegative, clinically normal mouse to WT mice, PrP TSE was detectable in the brain tissue (Race et al., 2002) . Indeed, whilst fewer than 200 people have developed clinical vCJD, it is likely that millions were exposed by consumption of BSE-contaminated beef, and it is possible that a number of these individuals may act as asymptomatic carriers of TSE infectivity. In the present study, we found evidence of subclinical TSE infection in two HuTg mice challenged with BASE (C18985-HuMM and C19409-HuVV; both negative for neuropathology and clinical signs of TSE disease). In these studies, our experiments may suggest that, during primary passage, low-level replication of BASE may occur in the HuTg mice. However, once within a susceptible host (Bov6), it is able to replicate efficiently. Indeed, the inefficient replication of the infectious TSE agent may explain why we were unable to detect any signs of TSE pathology in our HuTg mice challenged with BASE. Furthermore, our current experimental methods of detection may not be sensitive enough to detect low levels of PrP TSE . However, it is also possible that PrP TSE is not the infectious agent and that we are simply not searching for the correct markers for TSE infection in these animals. Indeed, the dissociation between PrP TSE and TSE infectivity has been shown in both natural and experimental cases (Andréoletti et al., 2011; Barron et al., 2007; Race et al., 2002) . Nevertheless, as it is known that PrP expression in the host is necessary for the development of neurodegeneration, PrP TSE remains an important diagnostic marker of TSE infection.
It is theoretically possible that residual inocula might be the cause of the TSE pathology observed in our Bov6 mice challenged with C18985-HuMM or C19409-HuVV; however, it would seem unlikely in these studies. Indeed, if this were the case, the expectation would be to see more cases of TSE pathology in all groups of inoculated mice. Furthermore, previous studies have shown the rapid clearance of prions from the brain following intracerebral inoculation (Safar et al., 2005a, b) , which would not agree with the retention of significant levels of BASE at 600 days post-inoculation. In previous studies, we observed that, following challenge of vCJD into Bov6 or HuTg mice, more clinical cases were observed in Bov6 mice (T. Hart & J. Manson, personal communication). These findings would support our data showing the lack of TSE pathology in the HuTg mice subpassaged with brain homogenate from BASE-or BSE-Hchallenged HuTg mice.
Transmission of BASE to overexpressing HuTg mice (encoding methionine at codon 129) has been demonstrated following primary passage (Béringue et al., 2008; Kong et al., 2008) ; however, in the present study, we were particularly interested in the discovery of subclinical infection in a HuVV mouse challenged with BASE, which has not been documented previously. Indeed, very few studies have been published investigating the transmission of TSEs into HuVV mice. Although all clinical cases of vCJD have been in individuals who are methionine homozygous at codon 129, studies in HuTg mice have shown that all three genotypes (MM, MV and VV) may be susceptible with differing incubation times (Bishop et al., 2006) . Indeed, transmission experiments have shown that only 1/16 HuVV Tg mice challenged with vCJD displayed TSE pathology compared with 11/17 HuMM Tg mice. However, although BSE-C and BASE are both cattle TSE strains, we cannot assume that the susceptibility of different human PrP genotypes would be the same between HuTg mice challenged with BSE-C or BASE. Indeed, other studies have suggested that the phenotypic features and PrP TSE characteristics of BASE bear resemblance to a subtype of sporadic CJD (sCJDMV2) (Casalone et al., 2004) . sCJDMV2 has been found to affect individuals who are methionine/valine heterozygous at codon 129 of the PrP gene (Parchi et al., 1999) , and this finding has raised the possibility that sCJDMV2 may actually not be a truly sporadic disease but may be acquired from the consumption of BASE-contaminated meat (Brown et al., 2006; Casalone et al., 2004) . Although our previous studies showed no TSE pathology on primary passage of BASE (Wilson et al., 2012b) or BSE-C (Bishop et al., 2006) to the HuTg mice, others have shown efficient transmission of BASE in mice overexpressing 129M human PrP, with higher levels of transmissibility than observed with BSE-C.
We have yet to perform subpassage from HuTg mice that received BSE-C to determine whether low-level agent replication also occurs in these mice. However, these data combined suggest that BASE may indeed transmit more efficiently to HuTg mice than BSE-C (Béringue et al., 2008) .
The potential existence of subclinical TSE infection in humans has several significant implications for public health, especially regarding the possibility of iatrogenic transmission of TSE disease from individuals who seem apparently healthy. Therefore, continued efforts must be made to ensure public health. However, whilst our findings suggest that low level replication of BASE can occur in hosts expressing human PrP, the efficiency of any potential human-to-human transmission appears to be low.
METHODS
Preparation of inocula. Brain tissue from the frontal and parietal cortices of a 15-year-old Piemontese cow (fallen stock) infected with BASE was supplied by Istituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle D'Aosta, Torino, Italy. The brainstem of a 15-year-old BSE-H-infected Prim Holstein cow (identified from a rendering plant) was supplied by the French TSE Reference Laboratory (Agence Nationale de Sécurité Sanitaire, Lyon, France). Primary transmissions have been described by Wilson et al. (2012a) . Seven BASE-challenged mouse brains and four BSE-H-challenged mouse brains were selected for subpassage (Table 1 ). All inocula were prepared from brain tissue in sterile saline at a concentration of 5 % (w/v). In order to prevent any possibility of cross-contamination of samples, all tissues were homogenized in clean, previously unused Dounce glass homogenizers that were discarded after single use. Samples were handled individually and the safety cabinet was decontaminated between each inoculum preparation. Positive-control Bov6 tissues were prepared on a different day from the HuMM and HuVV tissues (see Table 1 ). Full pathological characterization of source tissues (BASE, C. Casalone; BSE-H, T. Baron) was performed previously to confirm disease status.
Subpassage inoculation of transgenic mice. Gene-targeted Tg mice expressing bovine PrP (Bov6) or human PrP (HuMM, HuMV and HuVV) have been described previously (Bishop et al., 2006) . Tissues selected for subpassage covered a range of genotypes, ages and clinical status, and comprised nine HuTg mice inoculated with either BASE (n56) or BSE-H (n53) and two control Bov6 mice inoculated with BASE or BSE-H (Table 1) . Each of the 11 brains selected for subpassage was used to prepare a 5 % homogenate for use as an inoculum. Mice were injected by intracerebral inoculation into the right cerebral hemisphere under halothane anaesthesia. Each mouse received 0.02 ml 5 % brain homogenate and each homogenate was inoculated into a group of 12 HuTg mice of the same genotype as the inoculum and 12 Bov6 mice as controls. Homogenates from the two Bov6 control brains were each inoculated into groups of 12 HuMM and 12 Bov6 mice. In order to prevent any possible crosscontamination, inoculations were performed from one or two inocula only per day, with the safety cabinet cleaned and decontaminated between each set of inoculations. Of note, the HuMM and HuVV samples in Table 1 shown to transmit disease were inoculated on different days from the two Bov6 control tissues (C18275 and C19414; Table 1 ). From 100 days, mice were scored each week for signs of disease and killed by cervical dislocation at a pre-defined clinical end point or due to welfare reasons (Dickinson et al., 1968) . Due to the low number of culls for clinical TSE disease, survival times only were calculated for mice showing both PrP deposition and vacuolar pathology. Brains were recovered at post-mortem and onehalf of the brain was snap frozen in liquid nitrogen for biochemical analysis and the remaining half brain was fixed for histological processing. All mouse experiments were reviewed and approved by the Local Ethical Review Committee and performed under licence from the UK Home Office in accordance with the UK Animals (Scientific Procedures) Act 1986.
Vacuolation scoring. Sections were cut (6 mm) from each mouse brain and stained using haematoxylin and eosin. TSE-related vacuolation was assessed in nine grey-matter regions (medulla, cerebellum, superior colliculus, hypothalamus, thalamus, hippocampus, septum, retrospinal cortex, cingulate and motor cortex) and three regions of white matter (cerebellar white matter, midbrain white matter, and cerebral peduncle). Sections were scored on a scale of 0 (no vacuolation) to 5 (severe vacuolation) for the presence and severity of vacuolation, and mean vacuolation scores for each mouse group in each experiment were calculated and plotted against scoring areas to produce a lesion profile, as described previously (Bruce et al., 1997; Fraser & Dickinson, 1967) . Whilst the production of lesion profiles in pre-clinical mice is not standard practice, all mice that scored positively for vacuolation pathology were included whether or not clinical signs were present, due to the lack of clinical signs observed in any of the mice.
Immunohistochemical analysis of PrP deposition and glial activation in the brain. PrP TSE localization in the brain was assessed using immunohistochemistry. Following fixation in 10 % formal saline, brains were treated for 1.5 h in 98 % formic acid, dissected to expose several brain regions and embedded in paraffin. Sections (6 mm) were then autoclaved for 15 min at 121 uC and immersed in 95 % formic acid for 10 min prior to incubation with 0.44 mg antiPrP mAb 6H4 (Prionics) ml 21 at room temperature overnight. Secondary anti-mouse biotinylated antibody (Jackson Immuno Research Laboratories) was added at 2.5 mg ml 21 and incubated for 1 h at room temperature. Immunolabelling was performed using an ABC Elite kit (Vector Laboratories) and the signal was visualized by a reaction with hydrogen peroxide-activated diaminobenzidine. The presence of astrogliosis, a hallmark of prion disease, was assessed by incubating brain sections (6 mm) with 1.45 mg anti-glial fibrillary acidic protein (GFAP) antibody (Dako) ml 21 at room temperature for 1 h. To detect microglial activation, brain sections were pretreated using hydrated microwaving for 10 min prior to incubation with 0.05 mg anti-Iba1 antibody (Wako Chemicals) ml 21 at room temperature for 1 h. For both GFAP and anti-Iba-1 antibodies, 2.6 mg biotinylated secondary anti-rabbit antibody (Jackson Immno Research Laboratories) ml 21 was added for 1 h at room temperature. Both astrocytes and microglia were visualized by a reaction with hydrogen peroxide-activated diaminobenzidine.
Identification of PrP
TSE by immunoblotting. Frozen brain samples from Bov6 mice challenged with C18985-HuMM, C18275-Bov6 and C19414-Bov6 (and also brains from primary inoculations of Bov6 mice challenged with BASE, BSE-H and BSE-C) were homogenized at 10 % in an NP-40 buffer [0.5 % (v/v) NP-40, 0.5 % (w/v) sodium deoxycholate, 0.9 % (w/v) NaCl, 50 mM Tris/HCl (pH 7.5)] and clarified at 11 000 g for 15 min. Brain homogenate supernatant from the transgenic mice and controls was incubated with or without 20 mg proteinase K ml 21 for 1 h at 37 uC. The products were denatured and separated on a 12 % Novex Tris/glycine gel (Invitrogen) before transfer to PVDF membrane by Western blotting. The amount of brain tissue loaded onto the gels varied between 0.6 and 3 mg. PrP was identified with mAb 6H4 (0.1 mg ml 21 ) and bands were visualized using HRP-labelled anti-mouse secondary antibody (Jackson Immuno Research Laboratories) and a chemiluminescence substrate (Roche). Images were captured on radiographic film and with a Kodak 440CF digital imager.
Immunoassay for detection of PrP TSE in the brain. The IDEXX HerdChek* Bovine Spongiform Encephalopathy (BSE) Antigen Test
